Photodynamic laser therapy of basal-cell carcinoma of the lid.
Photodynamic therapy (PDT) remains an experimental approach for the treatment of small, mainly superficial malignant tumors. When given intravenously, hematoporphyrin derivative (HpD) selectively photosensitizes tumor tissue. Activated by light of 630 nm wave-length, HpD leads to tumor necrosis. This paper presents the results of PDT to eyelid basal-cell carcinomas in 21 patients. All lesions primarily responded to the treatment and became necrotic. A generalized photosensitization lasting for more than 4 weeks was seen in all patients. In five patients, lid malformations due to scar formation were noted, being marked in three cases. Ten patients showed a recurrence of tumor after 3-12 months. At present, PDT has no advantage over well-established therapies for basal-cell carcinomas of the eyelid.
Hintschich
C
C
Augenklinik, Ludwig-Maximilians-Universität, München, Germany.
Feyh
J
J
Beyer-Machule
C
C
Riedel
K
K
Ludwig
K
K
D000368:Aged; D000369:Aged, 80 and over; D002280:Basal Cell Carcinoma / Q000188:drug therapy*; D005142:Eyelid Neoplasms / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006415:Hematoporphyrins; D006801:Humans; D053685:Laser Therapy; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000188:drug therapy; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D016896:Treatment Outcome
D006415:Hematoporphyrins; D017319:Photosensitizing Agents; C071875:photosan III